Core Viewpoint - Adlai Nortye Ltd. has entered into an exclusive licensing agreement with ASK Pharm for its pan-RAS (ON) inhibitor AN9025, which is aimed at advancing cancer therapies in Greater China [1][2][3] Company Overview - Adlai Nortye is a clinical-stage biotechnology company focused on developing innovative cancer therapies, with a dual R&D presence in the U.S. and China [5] - The company is building a robust pipeline targeting next-generation cancer immunotherapies and RAS-driven cancers [5] Licensing Agreement Details - ASK Pharm will have exclusive rights to develop, manufacture, and commercialize AN9025 in mainland China, Hong Kong, and Macao, while Adlai Nortye retains worldwide rights outside this territory [2] - The total consideration for the agreement could reach up to RMB 1.6 billion (approximately USD 230 million), including an upfront payment and milestone payments exceeding USD 20 million, along with tiered royalties on net product sales [2] Product Information - AN9025 is an oral small molecule pan-RAS(ON) inhibitor designed to target a wide range of RAS mutations across various tumor types, showing potent efficacy in preclinical studies [4] - The company plans to initiate a phase I clinical study for AN9025 in the first quarter of 2026 [4] ASK Pharm Overview - ASK Pharm is a research-based pharmaceutical enterprise founded in 2003, focusing on innovative drug development in areas such as oncology and chronic diseases [6][7] - The company has a strong R&D pipeline with 48 major research projects, including several in advanced clinical trials [8]

Core Viewpoint - Arcus Biosciences is facing challenges following the discontinuation of the Phase 3 STAR-221 study, which has led to a significant decline in its stock price, but the company remains committed to its research and development efforts in cancer therapies and immunology [2][5]. Group 1: Company Overview - Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, collaborating with Gilead Sciences in the field of immuno-oncology [1]. - The company is recognized for its pioneering work in the oncology space despite competition from other biotech firms [1]. Group 2: Recent Developments - Citigroup has maintained a "Buy" rating for Arcus Biosciences, adjusting its price target from $56 to $44 due to the recent discontinuation of the Phase 3 STAR-221 study [2][5]. - The STAR-221 study evaluated a combination of anti-TIGIT antibody domvanalimab, anti-PD-1 antibody zimberelimab, and chemotherapy, but did not show improved overall survival compared to nivolumab plus chemotherapy, leading to its discontinuation [3]. Group 3: Stock Performance - Following the discontinuation of the STAR-221 study, Arcus Biosciences' stock price dropped approximately 14.38%, closing at $21.53 [4][5]. - The stock fluctuated between $20.35 and $23.98 during the trading day, with a market capitalization of approximately $2.32 billion and a trading volume of 7.16 million shares [4]. - Over the past year, the stock reached a high of $26.40 and a low of $6.50 [4]. Group 4: Future Focus - Despite recent setbacks, Arcus Biosciences continues to focus on its research and development efforts, particularly in its inflammation and immunology portfolio [4][5].

Core Insights - Karyopharm Therapeutics reported a total revenue of $44.0 million for Q3 2025, an increase from $38.8 million in Q3 2024, with U.S. net product revenue from XPOVIO (selinexor) at $32.0 million, reflecting an 8.5% increase year-over-year [1][11][19] - The company reaffirmed its full-year 2025 total revenue guidance of $140 million to $155 million and U.S. XPOVIO net product revenue guidance of $110 million to $120 million [1][14] - The Phase 3 SENTRY trial for myelofibrosis has completed enrollment, with top-line data expected in March 2026 [2][8] Financial Performance - Total revenue for Q3 2025 was $44.0 million, compared to $38.8 million in Q3 2024 [11] - U.S. net product revenue was $32.0 million, up from $29.5 million in Q3 2024, driven by gross-to-net favorability [6][11] - License and other revenue increased to $12.0 million in Q3 2025 from $9.3 million in Q3 2024, primarily due to milestone-related revenue from Menarini [12] - R&D expenses decreased to $30.5 million in Q3 2025 from $36.1 million in Q3 2024, attributed to lower clinical trial costs [13] - SG&A expenses were $26.6 million in Q3 2025, down from $27.6 million in Q3 2024, reflecting cost reduction initiatives [16] Clinical Development - The Phase 3 SENTRY trial for myelofibrosis enrolled 353 patients and is evaluating selinexor in combination with ruxolitinib [6][22] - The company continues to enroll patients in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with top-line data expected in mid-2026 [10][26] - Enrollment in the Phase 3 XPORT-MM-031 trial for multiple myeloma was completed in Q4 2024, with data expected in the first half of 2026 [7][13] Cash Position and Outlook - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $46.2 million, down from $109.1 million at the end of 2024 [20][43] - The company expects its existing liquidity will be sufficient to fund operations into Q2 2026 [14]

This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumpti ...

Company Overview - MAIA Biotechnology, Inc. is a biotechnology company founded in 2018 and headquartered in Chicago, Illinois, focused on discovering, developing, and commercializing novel cancer therapies addressing high unmet medical needs [2]. Recent Developments - MAIA Biotechnology advanced its lead candidate, ateganosine (THIO), with significant progress in clinical, regulatory, and pipeline fronts during Q2 2025 [4]. - The pivotal Phase 2 THIO-101 study in advanced non-small cell lung cancer (NSCLC) reported a median overall survival of 17.8 months among 22 third-line patients, with treatment being generally well tolerated [4]. - A new partial response was confirmed after 20 months of therapy, indicating the potential effectiveness of the treatment [4]. - The trial has expanded into Asia, with first dosing in Taiwan and ongoing screening in Europe and Asia [4]. - MAIA entered a master clinical supply agreement with Roche to evaluate ateganosine in combination with atezolizumab (Tecentriq®) across multiple hard-to-treat cancers [4]. - The FDA granted Fast Track designation for ateganosine in the treatment of NSCLC, enhancing the regulatory path for the drug [4]. Future Plans - MAIA plans to initiate studies in various cancers beyond NSCLC, including hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), colorectal cancer (CRC), breast, prostate, gastric, pancreatic, and ovarian cancers [4]. - The company aims to evaluate THIO-103 for first-line NSCLC and SCLC [4]. Valuation Insights - Recent updates have de-risked the THIO program in third-line NSCLC, with the Phase 2 THIO-101 dataset supporting a generally tolerable safety profile and durability of response [4]. - The valuation model has been revised to reflect recent financial results and share count, yielding a valuation of $10.27 per share, contingent on successful execution by the company [4].

Core Insights - Spartan Capital Securities, LLC announced the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. [1] - The offering involved the sale of 974,026 shares of Common Stock at a public offering price of $1.54 per share [2] - The gross proceeds of approximately $1.5 million will be used for general corporate purposes and working capital [3] Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on cancer drug development [2][8] - The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that enhances the effectiveness of chemotherapy and immunotherapy [8] - Clinical trials are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [8] Transaction Details - The offering was made under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [5] - Spartan Capital Securities served as the exclusive placement agent for this transaction [1][4] - The transaction reflects a focus on aligning innovative biotech companies with strategic capital for advancing therapies [4]

Core Insights - Crescent Biopharma, Inc. has completed its merger with GlycoMimetics, Inc. and will trade under the ticker symbol "CBIO" on Nasdaq starting June 16, 2025 [1][2] - The company has raised $200 million in a private financing round, which will support operations through 2027 and facilitate multiple pipeline milestones [1][3] - Crescent is advancing its lead program, CR-001, a PD-1 x VEGF bispecific antibody, with an IND application expected in Q4 2025 and proof-of-concept clinical data anticipated in H2 2026 [3][4] Company Overview - Crescent Biopharma aims to become a leading oncology company by developing innovative therapies for cancer patients, including its lead program and novel antibody-drug conjugates (ADCs) [4] - The company plans to leverage multiple modalities and established targets to advance transformative therapies for solid tumors [4] Pipeline Development - CR-001 is designed to replicate the pharmacology of ivonescimab, which has shown superior efficacy compared to pembrolizumab in a Phase 3 trial for non-small cell lung cancer [3][7] - The company is also developing two novel ADCs, CR-002 and CR-003, with CR-002 expected to enter clinical trials in mid-2026 [3]